Fairmount Funds Management LLC
Director; Director, 10% Owner · 14 filings · Latest: Jul 1, 2026
Apogee Therapeutics, Inc.
Cogent Biosciences, Inc.
CRESCENT BIOPHARMA, INC.
Damora Therapeutics, Inc.
Galecto, Inc.
Jade Biosciences, Inc.
Oruka Therapeutics, Inc.
Spyre Therapeutics, Inc.
Viridian Therapeutics, Inc.\DE
Zenas BioPharma, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ORKA | Fairmount Healthcare Fund II L.P. | — | Jul 1, 2026 | Proposed Sale | $84.43 | 3,553,410 | $300.0M | — | |
ORKA | Fairmount Funds Management LLC | Director, 10% Owner | Jul 1, 2026 | Sale | $84.43 | 3,553,410 | $300.0M | 1,131,954 | |
SYRE | Fairmount Healthcare Fund II L.P. | — | Jun 23, 2026 | Proposed Sale | $85.31 | 4,684,781 | $399.7M | — | |
SYRE | Fairmount Funds Management LLC | Director | Jun 23, 2026 | Sale | $85.31 | 4,684,781 | $399.7M | 0 | |
VRDN | Fairmount Funds Management LLC | Director, 10% Owner | May 11, 2026 | Purchase | $17.00 | 1,176,470 | $20.0M | 5,090,928 | |
ZBIO | Fairmount Funds Management LLC | Director | Mar 31, 2026 | Purchase | $20.00 | 150,000 | $3.0M | 2,359,025 | |
COGT | Fairmount Healthcare Fund II L.P. | — | Mar 31, 2026 | Proposed Sale | $34.66 | 7,000,000 | $242.6M | — | |
COGT | Fairmount Funds Management LLC | Director | Mar 31, 2026 | Sale | $34.66 | 7,000,000 | $242.6M | 5,503,418 | |
GLTO | Fairmount Funds Management LLC | Director, 10% Owner | Feb 9, 2026 | Option Exercise | $0.00 | 8,713,000 | — | 2,904,000 | |
COGT | Fairmount Funds Management LLC | Director | Jan 22, 2026 | Sale | $36.40 | 3,500,000 | $127.4M | 5,503,418 | |
APGE | Fairmount Funds Management LLC | Director | Jan 22, 2026 | Sale | $76.30 | 1,750,000 | $133.5M | 298,647 | |
COGT | Fairmount Healthcare Fund II L.P. | — | Jan 22, 2026 | Proposed Sale | $36.40 | 3,500,000 | $127.4M | — | |
APGE | Fairmount Healthcare Fund II L.P. | — | Jan 22, 2026 | Proposed Sale | $76.30 | 1,750,000 | $133.5M | — |